Literature DB >> 9853231

MRI of the uterus, uterine cervix, and vagina: diagnostic performance of dynamic contrast-enhanced fast multiplanar gradient-echo imaging in comparison with fast spin-echo T2-weighted pulse imaging.

P F Liu1, G P Krestin, R A Huch, S C Göhde, R F Caduff, J F Debatin.   

Abstract

The aim of this study was to compare the diagnostic performance of contrast-enhanced fast multiplanar gradient-echo (GRE) and T2-weighted fast spin-echo (FSE) image sets in the assessment of uterus, cervix, and vagina. Fast (up to 20 contiguous sections in 23 s) multiplanar GRE and FSE images of 45 patients referred for imaging of the female pelvis were evaluated retrospectively with regard to overall image quality and the ability to detect normal anatomic structures, as well as lesion conspicuity. Results were compared with histologic findings (n = 29) or clinical follow-up. Furthermore, a quantitative assessment of contrast-to-noise ratios among normal uterine and cervical structures as well as uterine lesions was performed for both sequences. On GRE images, uterine and cervical differentiation was best seen on the image sets acquired 15 and 60 s following contrast enhancement and results were significantly better compared with delayed images (p < 0.05). Delineation of the junctional zone was significantly (p < 0.05) better on FSE compared with GRE images; no significant difference was seen for the other anatomic structures. Overall image quality of GRE and FSE images was similar. Sensitivity for lesion detection based on both GRE and FSE images was 96% with a sensitivity of 93% for GRE, and 81% for FSE images alone, respectively. Using the extended McNemar chi 2 test, the difference in diagnostic performance between FSE and GRE revealed no significant difference, whereas the combination of both techniques performed better than FSE imaging alone (p < 0.05). The presented data suggest that dynamic contrast-enhanced GRE imaging should be part of an MR examination of the female pelvis. Combined GRE and FSE imaging provide an excellent sensitivity in the assessment of uterine and vaginal pathologies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9853231     DOI: 10.1007/s003300050569

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  7 in total

1.  The role of magnetic resonance imaging in oncology.

Authors:  Concepción González Hernando; Laura Esteban; Teresa Cañas; Enrique Van den Brule; Miguel Pastrana
Journal:  Clin Transl Oncol       Date:  2010-09       Impact factor: 3.405

2.  Staging of uterine cervical cancer with MRI: guidelines of the European Society of Urogenital Radiology.

Authors:  Corinne Balleyguier; E Sala; T Da Cunha; A Bergman; B Brkljacic; F Danza; R Forstner; B Hamm; R Kubik-Huch; C Lopez; R Manfredi; J McHugo; L Oleaga; K Togashi; K Kinkel
Journal:  Eur Radiol       Date:  2010-11-10       Impact factor: 5.315

Review 3.  Imaging tumour angiogenesis.

Authors:  Tony Jeswani; Anwar R Padhani
Journal:  Cancer Imaging       Date:  2005-12-01       Impact factor: 3.909

Review 4.  Dynamic contrast-enhanced magnetic resonance imaging: fundamentals and application to the evaluation of the peripheral perfusion.

Authors:  Yaron Gordon; Sasan Partovi; Matthias Müller-Eschner; Erick Amarteifio; Tobias Bäuerle; Marc-André Weber; Hans-Ulrich Kauczor; Fabian Rengier
Journal:  Cardiovasc Diagn Ther       Date:  2014-04

5.  The role of dynamic contrast-enhanced MRI in cancer diagnosis and treatment.

Authors:  Bariş Türkbey; David Thomasson; Yuxi Pang; Marcelino Bernardo; Peter L Choyke
Journal:  Diagn Interv Radiol       Date:  2009-11-02       Impact factor: 2.630

Review 6.  Imaging of tumor angiogenesis: functional or targeted?

Authors:  Baris Turkbey; Hisataka Kobayashi; Mikako Ogawa; Marcelino Bernardo; Peter L Choyke
Journal:  AJR Am J Roentgenol       Date:  2009-08       Impact factor: 3.959

Review 7.  Non-invasive assessment of vessel morphology and function in tumors by magnetic resonance imaging.

Authors:  Fabian Kiessling; Manfred Jugold; Eva C Woenne; Gunnar Brix
Journal:  Eur Radiol       Date:  2007-02-17       Impact factor: 7.034

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.